June 25, 2013 (Update) - On June 11, 2013, an article was published asserting that Celsion Corporations statistical findings from the Phase III study should be viewed with extreme skepticism and that having reviewed the Phase III results and subgroup analysis, all the doctors we spoke with unanimously believed that Celsion Corporation has no chance of regulatory approval.

Shares of Celsion Corporation (NASDAQ:CLSN) closed on June 21, 2013, at $1.22 per share.

Jan. 31, 2013 (Shareholders Foundation) -- An investigation on behalf of investors of Celsion Corporation (NASDAQ:CLSN) shares over potential securities laws violations by Celsion Corporation and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Celsion Corporation (NASDAQ:CLSN) concerning whether a series of statements by Celsion Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 30, 2012, Celsion Corporation announced the completion of the enrollment in its Pivotal Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer.

Shares of Celsion Corporation (NASDAQ:CLSN) grew from as low as $1.76 per share on May 18, 2012 to as high as $9.35 per share on Jan. 15, 2013,

Then on Jan. 31, 2013, before the market opened, Celsion Corporation announced the results of phase III HEAT Study of ThermoDox in Primary Liver Cancer.

Shares of Celsion Corporation (NASDAQ:CLSN) dropped from slightly over $8 per share on Jan. 30, 2013 to as low as $1.43 per share on Jan. 31, 2013.